Trial Profile
Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Docetaxel; Gemcitabine
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- 16 Oct 2022 Status changed from active, no longer recruiting to completed.
- 28 Sep 2022 Planned End Date changed from 1 Jul 2022 to 1 Dec 2022.
- 24 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Jul 2022.